Kalina Andreevska

Kalina Andreevska

Auto-generated profile, based on publicly available information

Kalina Andreevska

Faculty of Chemistry and Pharmacy, Sofia University, Sofia, Bulgaria

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2018 in Journal of IMAB – Annual Proceeding (Scientific Papers)
Verified
Journal Article
Open access
AKAntonia Kondova
Antonia Kondova
ATAnna Hristova Todorova
Anna Hristova Todorova
ATAntoaneta Tsvetkova
Antoaneta Tsvetkova
MAMariana Arnaoudova
Mariana Arnaoudova
KAKalina Andreevska
Kalina Andreevska
DGDaniela Grekova-Kafalova
Daniela Grekova-Kafalova

2 August 2024 in Pharmacia
Verified
Journal Article
Open access
PDF file
LPLora Petrova
Lora Petrova
KAKalina Andreevska
Kalina Andreevska
IPIva Parvova
Iva Parvova
VPValentina Petkova
Valentina Petkova
In recent years, incretin mimetics have become an important part of type 2 diabetes mellitus therapy. The aim of this study is to evaluate the efficacy and safety of glucagon-like peptide-1 (GLP-1) receptor agonists. We performed a literature search of scientific publications in MEDLINE and Central Library of Medicine databases by predefined keywords for the period 2004 to 2023 containing information for the efficacy and safety of GLP-1 receptor agonists. The systematic review is in accordance with the PRISMA standard and the PICOS tool. There is strong evidence to support the use of GLP-1 agonists in overweight or obese patients who have cardiovascular disease, impaired renal function or are at high risk of hypoglycaemia. The safety profiles of all representatives of this class are similar. Semaglutide and Tirzepatide demonstrated the highest efficacy in reducing glycated hemoglobin (HbA1c) - 1.70% and 2.37%, respectively. We found the superiority of GLP-1 receptor agonists over other antidiabetic medicinal prodycts in terms of HbA1c reduction and weight loss without the risk of hypoglycemic episodes.

21 November 2023 in Pharmacia
Verified
Journal Article
Open access
PDF file
VGVeselina S Goranova-Marinova
Veselina S Goranova-Marinova
DGDaniela Grekova-Kafalova
Daniela Grekova-Kafalova
VGVania Georgieva
Vania Georgieva
KAKalina Andreevska
Kalina Andreevska
Yana GvozdevaYana Gvozdeva
Yana Gvozdeva
ZGZhanet Grudeva-Popova
Zhanet Grudeva-Popova
Aim. The aim of this study is to evaluate treatment retrospectively, response to the therapy and outcomes in patients with chronic myeloid leukemia (CML) and to what extent the European recommendations of LeukemiaNET (ELN) are followed at the Hematology Clinic, University Hospital “St. Georgi”, MU Plovdiv. Methods. All patients with Ph+, BCR-ABL1+ CML who were treated and observed between 01.01.2018 and 12.31.2022 at the clinic were included in the study and were analyzed retrospectively. Results. One hundred and eighty-eight patients with a mean age of 61.26 (21–91) years were analyzed. 151 (80.3%) were in chronic phase (CP), 27 (14.4%) in accelerating one and 10 (5.3%) in blast crisis. The actual overall survival rate was 79.26%, while for CP it is very high – 86.75%, and the mortality rate is 20.74%. All patients received some form of tyrosine kinase inhibitors therapy (TKIs-therapy). The first line TKI was imatinib in 120 patients (64%), and 68 (36%) received a second-generation TKI. Treatment response was monitored with TKIs by RT-qPCR. Conclusion. CML patients treated in the hematology clinic receive standard care in accordance with ELN and BMSH recommendations. Overall survival (OS) in routine care is comparable to published data from international studies. Molecular monitoring provides a good basis for disease control in CP. There are unmet needs in the treatment of patients in advanced stages.

26 June 2024 in Pharmacia
Verified
Journal Article
Open access
PDF file
VGVeselina Goranova-Marinova
Veselina Goranova-Marinova
DGDaniela Grekova-Kafalova
Daniela Grekova-Kafalova
KAKalina Andreevska
Kalina Andreevska
VGVania Georgieva
Vania Georgieva
Yana GvozdevaYana Gvozdeva
Yana Gvozdeva
VPValentina Petkova
Valentina Petkova
Summary: Chronic myelogenous leukemia (CML) is a pluripotent hemopoietic stem cell malignancy characterized by the presence of a BCR-ABL1 fusion gene derived from a balanced translocation between the long arms of chromosomes 9 and 22 [t(9;22) (q34; q11)] known as the Philadelphia (Ph) chromosome. CML is an acquired hematopoietic stem cell disease common to myelo- and lymphopoiesis, characterized by uncontrolled proliferation of granulopoiesis (Shuvaev et al. 2015; Yordanov and Varbanova 2019). Relevance and goals: Second-generation tyrosine kinase inhibitors (TKIs) (nilotinib, dasatinib, and bosutinib) have an advantage over imatinib (first-generation) in the frequency and speed of achieving cytogenetic and molecular responses in the treatment of chronic myelogenous leukemia (CML), but they cause severe adverse effects and are much more expensive than imatinib, especially if we compare them to the prices of the registered generic products of Imatinib and Dasatinib. “Novartis Tasigna® trial shows superior results to Glivec® in patients with early-stage chronic myeloid leukemia”, reported on 10/20/2021 by Pierre Perrin-Montlouis. In the first direct comparison of these two oral therapies back in 2009 (Тasigna (nilotinib) 2009), as first-line treatment for CML, the results of Tasigna showed statistically significant improvement over Glivec in every measure of efficacy, including major molecular response (MMR), complete cytogenetic response (CCyR) and prevention of progression to accelerated or blast phase, with responses achieved faster in the Tasigna group than in the Glivec group. Furthermore, in the last ten years, CML patients who have achieved a stable deep molecular response for at least 2 years have been included in clinical trials for the management of treatment-free remission (TFR) (Kim et al. 2013; Saußele et al. 2016). On the other hand, the ever-increasing costs of diagnosis, treatment and monitoring of the response of CML to the various therapeutic strategies require conducting pharmacoeconomic analyses of the cost-effectiveness and cost-utility types in order to evaluate which are the cost-effective strategies with a view to introducing them into therapeutic practice. The present study aims to analyze the pharmacoeconomic efficiency of the TKI inhibitors used by the patients with CML-CP in the first and second lines, treated in the hematology clinic at UMHAT “St. George”, MU- Plovdiv during the period 2018–2022. Methods: An economic analysis of the medicinal use of TKIs for a 5-year period (2018–2022) was performed at the national level according to data from the National Health Insurance Fund and the availability, accessibility, and usability of original and generic TKIs in Bulgaria were evaluated. The direct medical costs for the therapy of all patients were calculated, including the costs of the TKI therapy, laboratory tests, and monitoring of the molecular response for the entire treatment period from the appointment of the TKI therapy until the end of 2022. A comparative analysis was conducted to assess the cost-effectiveness of the different therapeutic strategies with TKIs on the first and second lines of treatment of patients with CML-CP in the hematology clinic at UMHAT “St. George” Medical University, Plovdiv, using the decision analysis method and conducting one-way and probalistic sensitivity analyses. Results: The sensitivity analyzes of all pharmacoeconomic models showed the robustness and reliability of the obtained results. The threshold limits of medical costs and the frequency of achieving a deep molecular response determining the choice of first- and second-generation tyrosine kinase inhibitors as first- and second-line therapy for patients with chronic myeloid leukemia in the chronic phase have been determined. Prescribing doctors prefer the original MPs to generic analogues, which is also assumed by the current regulations, according to which even for expensive MPs dispensing by protocols, the prescription is by trade and not by international non-proprietary names (INN), which is why the use of the much cheaper generic MPs is negligibly low compared to original MPs. A personalized approach to the patient’s therapy and monitoring the patient’s molecular response to it, as well as stopping therapy in 25–30% of patients suitable to stop it safely when in TFR phase with a probability of more than 50% of not having a relapse will save additional costs that, by improving the cost-effectiveness of therapy for patients with CML, will be directed towards the treatment of new patients with this or other diseases. Conclusion: These pharmacoeconomic models can be applied to improve diagnostic and therapeutic standards in clinical practice and for the efficient use of the very limited resources for health care in countries like Bulgaria. The conducted cost-effectiveness analyses confirmed that the hematologists at the University Center in Plovdiv adhere to the recommendations of Leukemia Net and the Bulgarian Medical Society of Hematology and achieve not only good therapeutic but also pharmacoeconomic efficiency in the treatment of CML-СР patients in first- and second- line therapy.

18 August 2023 in Pharmacia
Verified
Journal Article
Open access
PDF file
VPValentina Petkova
Valentina Petkova
APAnna Peneva
Anna Peneva
KAKalina Andreevska
Kalina Andreevska
EHEmil Hristov
Emil Hristov
DGDaniela Grekova-Kafalova
Daniela Grekova-Kafalova
Milen Ventsislavov DimitrovMilen Ventsislavov Dimitrov
Milen Ventsislavov Dimitrov
Adherence to antihypertensive medications is the cornerstone for achieving metabolic syndrome control. The aim of this study was to explore how the pandemic has affected the adherence of patients with high BP to prescribed antihypertensive drugs. This multicentre observational study utilized self-completed questionnaires among patients between June and November 2020. Overall, 842 patients were included in the study. The likelihood of adherence was assessed using the 5‐item version of the Medication Adherence Report Scale (MARS-5Professor Rob Horne). The average MARS score of the sample was 16.81, the median was 4.162, and the most common value was 3 (24.5% of respondents) for the patients treated during the pandemic. The study suggests that several sociodemographic factors but not the COVID pandemic play a role in treatment adherence.

19 February 2026 in Pharmacia
Verified
Journal Article
Open access
ISIana Simova
Iana Simova
VPValentina Petkova
Valentina Petkova
SOSava Ognyanov
Sava Ognyanov
KAKalina Andreevska
Kalina Andreevska
Milen Ventsislavov DimitrovMilen Ventsislavov Dimitrov
Milen Ventsislavov Dimitrov
This review traces European medical device regulation from fragmented national systems to the harmonized framework established by Regulation (EU) 2017/745 (MDR) and Regulation (EU) 2017/746 (IVDR). It examines the pre-harmonization period (1957–1985), characterized by diverse national approaches in Western and Eastern Europe, including Bulgaria’s regulatory development during the post-communist transition. It explores the New Approach to technical harmonization (1985), the directive era (1990–2000), and how regulatory crises—including the Guidant pacemaker failures, the DePuy ASR hip prosthesis scandal, and the PIP breast implant fraud—served as stress tests confirming the necessity of reforms. Special attention is given to emerging challenges from artificial intelligence in medical devices following the adoption of the AI Act (Regulation (EU) 2024/1689).